These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 34043455)

  • 21. Treatment of older patients with acute myeloid leukaemia.
    Ferrara F
    Lancet; 2010 Dec; 376(9757):1967-8. PubMed ID: 21131041
    [No Abstract]   [Full Text] [Related]  

  • 22. Enasidenib for relapsed/refractory acute myeloid leukemia with IDH2 mutations: optimizing the patient experience.
    Roboz GJ
    Clin Adv Hematol Oncol; 2018 May; 16(5):322-325. PubMed ID: 29851927
    [No Abstract]   [Full Text] [Related]  

  • 23. Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing.
    Wang B; Liu Y; Hou G; Wang L; Lv N; Xu Y; Xu Y; Wang X; Xuan Z; Jing Y; Li H; Jin X; Deng A; Wang L; Gao X; Dou L; Liang J; Chen C; Li Y; Yu L
    Oncotarget; 2016 May; 7(22):32065-78. PubMed ID: 27062340
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Allogeneic Transplantation for Unfavorable-Risk Acute Myeloid Leukemia.
    Fernandez HF
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S70-2. PubMed ID: 26297283
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low NKD1 expression predicts adverse prognosis in cytogenetically normal acute myeloid leukemia.
    Zhou JD; Yao DM; Han L; Xiao GF; Guo H; Zhang TJ; Li XX; Yuan Q; Yang L; Lin J; Qian J
    Tumour Biol; 2017 Apr; 39(4):1010428317699123. PubMed ID: 28443469
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [How I treat... Acute myeloid leukemia in older patients with good performance status].
    Lejeune M; Beguin Y; De Prijck B; Fassotte MF; Fillet G; Baron F
    Rev Med Liege; 2008 Feb; 63(2):59-63. PubMed ID: 18372541
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HOXA/PBX3 knockdown impairs growth and sensitizes cytogenetically normal acute myeloid leukemia cells to chemotherapy.
    Dickson GJ; Liberante FG; Kettyle LM; O'Hagan KA; Finnegan DP; Bullinger L; Geerts D; McMullin MF; Lappin TR; Mills KI; Thompson A
    Haematologica; 2013 Aug; 98(8):1216-25. PubMed ID: 23539541
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted therapy in acute myeloid leukemia: current status and new insights from a proteomic perspective.
    van Dijk AD; de Bont ESJM; Kornblau SM
    Expert Rev Proteomics; 2020 Jan; 17(1):1-10. PubMed ID: 31945303
    [No Abstract]   [Full Text] [Related]  

  • 29. CPX-351: changing the landscape of treatment for patients with secondary acute myeloid leukemia.
    Talati C; Lancet JE
    Future Oncol; 2018 May; 14(12):1147-1154. PubMed ID: 29378418
    [TBL] [Abstract][Full Text] [Related]  

  • 30. JSH Practical Guidelines for Hematological Malignancies, 2018: I. Leukemia-1. Acute myeloid leukemia (AML).
    Kiyoi H; Yamaguchi H; Maeda Y; Yamauchi T
    Int J Hematol; 2020 May; 111(5):595-613. PubMed ID: 32207053
    [No Abstract]   [Full Text] [Related]  

  • 31. Therapy for acute myeloid leukemia and acute lymphoblastic leukemia in adults.
    Geller RB; Larson RA
    Curr Opin Oncol; 1991 Feb; 3(1):30-8. PubMed ID: 2043696
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Subgroup specific therapy effects in AML: AMLCG data.
    Büchner T; Hiddemann W; Berdel WE; Wörmann B; Schoch C; Fonatsch C; Löffler H; Haferlach T; Ludwig WD; Maschmeyer G; Staib P; Balleisen L; Grüneisen A; Aul C; Lengfelder E; Hehlmann R; Kern W; Serve HL; Mesters RM; Eimermacher H; Frickhofen N; Kienast J; Giagounidis A; Sauerland MC; Heinecke A;
    Ann Hematol; 2004; 83 Suppl 1():S100-1. PubMed ID: 15124694
    [No Abstract]   [Full Text] [Related]  

  • 33. [Current diagnosis and treatment for pediatric acute myeloid leukemia].
    Shiba N
    Rinsho Ketsueki; 2017; 58(4):389-399. PubMed ID: 28484171
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic Resistance in Acute Myeloid Leukemia: The Role of Non-Coding RNAs.
    Zebisch A; Hatzl S; Pichler M; Wölfler A; Sill H
    Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27973410
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advances in the treatment of elderly and frail patients with acute myeloid leukemia.
    Amadori S; Del Principe MI; Venditti A
    Curr Opin Oncol; 2014 Nov; 26(6):663-9. PubMed ID: 25162330
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune Checkpoint Inhibitors in Acute Myeloid Leukemia: Novel Combinations and Therapeutic Targets.
    Stahl M; Goldberg AD
    Curr Oncol Rep; 2019 Mar; 21(4):37. PubMed ID: 30904967
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fatal stimulation of acute myeloid leukemia blasts by pegfilgrastim.
    Duval C; Boucher S; Moulin JC; Gourieux B; Mauvieux L; Leveque D; Herbrecht R
    Anticancer Res; 2014 Nov; 34(11):6747-8. PubMed ID: 25368285
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pathogenic and therapeutic roles of cytokines in acute myeloid leukemia.
    Karimdadi Sariani O; Eghbalpour S; Kazemi E; Rafiei Buzhani K; Zaker F
    Cytokine; 2021 Jun; 142():155508. PubMed ID: 33810945
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comprehensive molecular landscape in patients older than 80 years old diagnosed with acute myeloid leukemia: A study of the French Hauts-de-France AML observatory.
    Renaud L; Nibourel O; Marceau-Renaut A; Gruson B; Cambier N; Lionne-Huyghe P; Choufi B; Rodriguez C; Frimat C; Plantier I; Stalnikiewicz L; Bemba M; Berthon C; Marolleau JP; Quesnel B; Preudhomme C; Duployez N
    Am J Hematol; 2019 Jan; 94(1):E24-E27. PubMed ID: 30358899
    [No Abstract]   [Full Text] [Related]  

  • 40. Tim-3 is highly expressed in T cells in acute myeloid leukemia and associated with clinicopathological prognostic stratification.
    Li C; Chen X; Yu X; Zhu Y; Ma C; Xia R; Ma J; Gu C; Ye L; Wu D
    Int J Clin Exp Pathol; 2014; 7(10):6880-8. PubMed ID: 25400771
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.